Diagnostic Imaging Clinical Trial
Official title:
Comparison of PET/CT vs. PET/MRI
| Verified date | April 2021 |
| Source | Stanford University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.
| Status | Completed |
| Enrollment | 53 |
| Est. completion date | February 5, 2020 |
| Est. primary completion date | November 30, 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | INCLUSION CRITERIA - Cancer diagnosis - Capable of complying with study procedures - Able to remain still for duration of imaging procedure (approximately 90 minutes total) - Written informed consent EXCLUSION CRITERIA - Pregnant or nursing - Metallic implants - Impaired renal function |
| Country | Name | City | State |
|---|---|---|---|
| United States | Stanford University, School of Medicine | Palo Alto | California |
| Lead Sponsor | Collaborator |
|---|---|
| Stanford University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Absolute Accuracy of SUV Max of PET/CT vs PET/MRI | Standardized uptake value max (SUVmax) is a measurement of the maximum radiopharmaceutical uptake value within the region of interest (ROI). SUVmax is calculated as the ratio of activity concentration:injected dose/body weight. The outcome is reported as the mean SUVmax with standard deviation (SD), reported for 8 specific organs or bodily locations. | 4 hours | |
| Secondary | PET/CT vs PET/MRI Difference in Standardized Uptake Value Max (SUVmax), by Radiotracer | Standardized uptake value max (SUVmax) is a measurement of the maximum radiopharmaceutical uptake within the region of interest (ROI). Relative accuracy of a particular radiotracer in a particular tissue is determined by expressing the absolute accuracy (obtained in the primary outcome measure) in terms of percent difference between SUVmax values obtained from PET/CT and PET/MR. Percentage difference is expressed as the difference of the means in SUVmax for the PET/CT and PET/MRI scan procedures for the particular radiotracer, divided by the mean between the values for the 2 scan procedures. The closer the percent difference is to 0%, the better the agreement between the two scanners. The outcome is expressed as the percentage difference, a number without dispersion. |
estimated average of 2 hours |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01415414 -
Observational Study of Ultravist in Patients Requiring CECT
|
N/A | |
| Terminated |
NCT00975299 -
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT05036460 -
Real-time Sonography in Detecting Inadvertent Esophageal Intubation Among Difficult Intubation Patients
|
N/A | |
| Recruiting |
NCT05610098 -
Gene Expression Profiles in Spinal Tuberculosis.
|
||
| Completed |
NCT01009359 -
Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00244140 -
Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
|
Phase 3 | |
| Completed |
NCT02980081 -
Abdominal Plain X-ray in the Emergency Departement
|
N/A | |
| Completed |
NCT01205321 -
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05823857 -
Effect of an Aquatic Exercise Program in Patients With Chronic Low Back Pain
|
N/A | |
| Recruiting |
NCT04859634 -
Real-time Artificial Intelligence System for Detecting Multiple Ocular Fundus Lesions by Ultra-widefield Fundus Imaging
|
||
| Terminated |
NCT03167190 -
Ultrasound-Assisted Lumbar Puncture
|
N/A | |
| Completed |
NCT01297088 -
PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.
|
Phase 1 | |
| Completed |
NCT01089998 -
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
|
Phase 1 | |
| Completed |
NCT00347022 -
A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications
|
Phase 4 | |
| Completed |
NCT00876083 -
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
|
N/A | |
| Completed |
NCT01411449 -
Primovist Post-marketing Surveillance in Japan
|
N/A | |
| Completed |
NCT01153607 -
Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00709852 -
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
|
Phase 3 | |
| Terminated |
NCT00659776 -
MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation
|
Phase 2 | |
| Recruiting |
NCT05733377 -
Non-invasive Imaging Technique for the Study of Lordosis in Pregnant Women and Its Relationship to Birth Outcome
|